4Brice E Managing relapsed and refractory Hodgkin lymphoma. Br J Hematol, 2008, 141:3-13.
5Appelbaum FR. Hematopoietic cell transplantation for non- Hodgkin' s lymphorna: yesterday, today, and tomorrow. J Clin Oncol, 2008, 26:2927-2929.
6Kaplan LD, Swaus D J, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non- Hodgkin' s lymphoma associated wilh human immunodefiei- eney virus infection. N Engl J Med, 1997, 336: 1641-1648.
7Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lympho- ma in the rituximab era. J Clin Oncol, 2010, 28:4184-4190.
8Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy- sensitive non- Hodgkin' s lympho- ma. N Engl J Med, 1995, 333:1540-1545.
9Vose JM, Rowlings PA, Lazarus HM, et al. Multivariate analysis of autotransplants for patients with aggressive non- Hodgkin' s lymphoma failing primary induction therapy [ abstract ] .Blood, 1997,90 Suppl 1:594a.
10Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol, 1994, 12: 1169-1176.
